US20060199972A1 - Methods for producing gallium and other oxo/hydroxo-bridged metal aquo clusters - Google Patents
Methods for producing gallium and other oxo/hydroxo-bridged metal aquo clusters Download PDFInfo
- Publication number
- US20060199972A1 US20060199972A1 US11/352,445 US35244506A US2006199972A1 US 20060199972 A1 US20060199972 A1 US 20060199972A1 US 35244506 A US35244506 A US 35244506A US 2006199972 A1 US2006199972 A1 US 2006199972A1
- Authority
- US
- United States
- Prior art keywords
- metal
- reducing agent
- group
- formula
- organic reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 52
- 239000002184 metal Substances 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims description 42
- 229910052733 gallium Inorganic materials 0.000 title claims description 29
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 title description 27
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 19
- 150000002739 metals Chemical class 0.000 claims abstract description 11
- 229910001960 metal nitrate Inorganic materials 0.000 claims abstract description 8
- 230000001747 exhibiting effect Effects 0.000 claims abstract 6
- 239000000203 mixture Substances 0.000 claims description 26
- 229910002651 NO3 Inorganic materials 0.000 claims description 25
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 25
- 239000013078 crystal Substances 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 229910052782 aluminium Inorganic materials 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 229910052738 indium Inorganic materials 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- 125000001931 aliphatic group Chemical group 0.000 claims description 8
- 229910052742 iron Inorganic materials 0.000 claims description 7
- 238000001704 evaporation Methods 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 229910052759 nickel Inorganic materials 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000002832 nitroso derivatives Chemical class 0.000 claims description 3
- 150000003003 phosphines Chemical class 0.000 claims description 3
- 150000003462 sulfoxides Chemical class 0.000 claims description 3
- 229910052772 Samarium Inorganic materials 0.000 claims description 2
- 229910052776 Thorium Inorganic materials 0.000 claims 3
- 229910052748 manganese Inorganic materials 0.000 claims 3
- NLRKCXQQSUWLCH-IDEBNGHGSA-N nitrosobenzene Chemical group O=N[13C]1=[13CH][13CH]=[13CH][13CH]=[13CH]1 NLRKCXQQSUWLCH-IDEBNGHGSA-N 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical class N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- NLRKCXQQSUWLCH-UHFFFAOYSA-N nitrosobenzene Chemical compound O=NC1=CC=CC=C1 NLRKCXQQSUWLCH-UHFFFAOYSA-N 0.000 abstract description 21
- 150000003839 salts Chemical class 0.000 abstract description 13
- 150000002823 nitrates Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 description 27
- 238000003786 synthesis reaction Methods 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 14
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 14
- 238000007254 oxidation reaction Methods 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Inorganic materials [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 10
- 230000003647 oxidation Effects 0.000 description 10
- 238000003384 imaging method Methods 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- -1 for example Chemical compound 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 6
- 150000002923 oximes Chemical class 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 0 *C.*C.CO.O=NC1=CC=CC=C1.O=[N+]([O-])C1=CC=CC=C1 Chemical compound *C.*C.CO.O=NC1=CC=CC=C1.O=[N+]([O-])C1=CC=CC=C1 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 229910021645 metal ion Inorganic materials 0.000 description 5
- 150000004005 nitrosamines Chemical class 0.000 description 5
- 238000006053 organic reaction Methods 0.000 description 5
- 238000001308 synthesis method Methods 0.000 description 5
- GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 150000002258 gallium Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical class [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 239000011162 core material Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940006110 gallium-67 Drugs 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 125000004971 nitroalkyl group Chemical group 0.000 description 3
- 238000002600 positron emission tomography Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- JLDSOYXADOWAKB-UHFFFAOYSA-N aluminium nitrate Chemical compound [Al+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O JLDSOYXADOWAKB-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 150000002259 gallium compounds Chemical class 0.000 description 2
- 229940044658 gallium nitrate Drugs 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000005291 magnetic effect Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- GYHNNYVSQQEPJS-YPZZEJLDSA-N Gallium-68 Chemical compound [68Ga] GYHNNYVSQQEPJS-YPZZEJLDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- KKKSUGSJGGUVKG-UHFFFAOYSA-N O=NC1=CC=CC=C1.O=[N+]([O-])C1=CC=CC=C1 Chemical compound O=NC1=CC=CC=C1.O=[N+]([O-])C1=CC=CC=C1 KKKSUGSJGGUVKG-UHFFFAOYSA-N 0.000 description 1
- XURCIPRUUASYLR-UHFFFAOYSA-N Omeprazole sulfide Chemical compound N=1C2=CC(OC)=CC=C2NC=1SCC1=NC=C(C)C(OC)=C1C XURCIPRUUASYLR-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 241000278713 Theora Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229910021513 gallium hydroxide Inorganic materials 0.000 description 1
- CKHJYUSOUQDYEN-UHFFFAOYSA-N gallium(3+) Chemical class [Ga+3] CKHJYUSOUQDYEN-UHFFFAOYSA-N 0.000 description 1
- QZQVBEXLDFYHSR-UHFFFAOYSA-N gallium(III) oxide Inorganic materials O=[Ga]O[Ga]=O QZQVBEXLDFYHSR-UHFFFAOYSA-N 0.000 description 1
- GYHNNYVSQQEPJS-AHCXROLUSA-N gallium-66 Chemical compound [66Ga] GYHNNYVSQQEPJS-AHCXROLUSA-N 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical class [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002472 indium compounds Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical class [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 229910001463 metal phosphate Inorganic materials 0.000 description 1
- 238000005649 metathesis reaction Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M nitrite group Chemical group N(=O)[O-] IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical class [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G15/00—Compounds of gallium, indium or thallium
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F7/00—Compounds of aluminium
- C01F7/66—Nitrates, with or without other cations besides aluminium
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
- C01G1/00—Methods of preparing compounds of metals not covered by subclasses C01B, C01C, C01D, or C01F, in general
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/30—Three-dimensional structures
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
- C01P2002/77—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by unit-cell parameters, atom positions or structure diagrams
Definitions
- the disclosure pertains to methods of producing oxo/hydroxo-bridged metal aquo nanoclusters.
- Keggin structures are known. Representative Keggin structures having a central tetrahedral Al(O)4 core are illustrated in FIGS. 6A-6C . These structures correspond to so-called ⁇ -Keggin (Al 13 ), ⁇ -Keggin (Al 13 ), and an Al 30 cluster. These and other Keggin structures are described in Casey et al., Reviews in Mineralogy & Geochemistry 44:167-190 (2001).
- Keggin-like clusters typically involve lengthy reaction times and harsh reaction conditions.
- synthesis of the Keggin-like Al cluster [Al 13 ( ⁇ 3 -OH) 6 ( ⁇ 2 -OH) 18 (H 2 O)24]Cl 15 requires a 4-5 month synthesis/crystallization procedure as reported by Seichter et al., Eur. J. Inorg. Chem. (1998).
- Keggin-like Al cluster [Al 8 ( ⁇ 3-OH) 2 ( ⁇ 2-OH) 12 (H 2 O) 18 ](SO 4 ) 5 requires a 7 year synthesis/crystallization procedure as reported by Casey et al., Inorg. Chem. (2005).
- Synthesis of the Keggin-like Al cluster [Al 15 ( ⁇ 3-O) 4 ( ⁇ 3-OH) 6 ( ⁇ 2 -OH) 14 (hpdta)] 3 requires an 8 day ligand-shell stabilized synthesis as reported in Schmitt et al., Angew. Chem. (2001). For convenience, diagrams of these Al(O) 6 core materials are shown in FIGS. 7A-7C .
- Nanoscale inorganic clusters can be formed synergistically with a mild organic oxidation reaction.
- a tridecameric cluster [Ga 13 ( ⁇ 3 -OH) 6 ( ⁇ -OH) 18 (H 2 O) 24 ](NO 3 ) 15 (referred to herein as Ga 13 ) forms when a mild organic reducing agent (such as nitrosobenzene) facilitates the conversion.
- a mild organic reducing agent such as nitrosobenzene
- This is an example of an organic reaction mediating an inorganic transformation, and provides a link between organic and inorganic synthesis that allows both processes to occur under aerobic, ambient conditions with good yields.
- Previous syntheses of inorganic clusters suffer from extremely long reaction times (months to years), harsh conditions, and/or poor yields.
- the mild organic oxidation reaction can be tolerant to many functional groups, and other mild organic oxidation reactions can be similarly implemented.
- the representative clusters described herein have applications in areas ranging from environmental chemistry (mimics for mineral surfaces) to the cracking of gas oil (pillaring agents for montmorillonite clay catalysts).
- Other nanocluster applications include: models for the active sites of minerals for catalysis, single molecule magnets (with magnetic or paramagnetic metal ions), magnetic memory devices, conductive/semiconductive metal oxide layers for circuits and integrated circuits, high-density metal-based contrast agents (e.g., 67 Ga positron emission tomography (PET) contrast agents), osmotic-type molecular transport phenomena using the high charge of the clusters, environmental remediation of toxic metal ions, and the use of the clusters as synthons for materials via aquo ligand exchange reactions.
- PET positron emission tomography
- the present disclosure is directed to synthesis methods that can form previously synthesized inorganic clusters or previously unavailable inorganic clusters.
- the synthesis methods are typically based on functional group tolerant organic oxidations that occur under “mild” conditions, i.e., typically do not require temperature, pressure, or pH extremes, or lengthy reaction times.
- Representative clusters include Ga 13 , A 13 , Ga 7 In 6 , and GaAl 12 .
- One aspect of the present disclosure includes novel compounds, compositions and methods for using such compounds and compositions for use in scintigraphy or PET or other diagnostic imaging applications.
- FIGS. 1A-1B are space-filling representations of a single crystal X-ray structure of a Ga 13 nanocluster.
- FIGS. 2A-2B are wireframe representations of a single crystal X-ray structure of a Ga 13 nanocluster.
- FIG. 3A is an X-ray powder diffraction pattern obtained from Ga 13 produced as described herein.
- FIG. 3B is an X-ray power diffraction pattern obtained by calculation.
- FIGS. 4A-4B are space-filling representations of Al 13 derived from the measured single crystal X-ray structure of Al 13 .
- FIGS. 5A-5B are space-filling representations of In 6 Ga 7 derived from the measured single crystal X-ray structure of In 6 Ga 7 .
- FIGS. 6A-6C are space-filling representations of ⁇ -Keggin, Al 13 , ⁇ -Keggin (Al 13 ), and an Al 30 cluster, respectively.
- FIGS. 7A-7C illustrate [Al 13 ( ⁇ 3 -OH) 6 ( ⁇ 2 -OH) 18 (H 2 O) 24 ]Cl 15 , [Al 8 ( ⁇ 3 -OH) 2 ( ⁇ 2 -OH) 12 (H 2 O) 18 ](SO 4 ) 5 , and [Al 15 ( ⁇ 3 -O) 4 ( ⁇ 3 -OH) 6 ( ⁇ 2 -OH) 14 (hpdta)] 3 , respectively.
- Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.
- Nanoscale cluster compounds or “nanocluster” generally refers to clusters having dimensions of from about 0.1 nm to 200 nm, preferably between about 0.2 nm and 100 nm, more preferably between about 0.5 nm and 50 nm, and still more preferably between about 1 nm and 5 nm.
- a gallium nanocluster is disk shaped and has a diameter of about 2 nm and a thickness of about 1 nm. Materials are referred to as soluble or appreciably soluble if millimolar concentrations can be achieved under typical reaction conditions such as ambient temperatures.
- Metal salts generally are selected from a group consisting of salts of aluminum, germanium, indium, gallium, iron, manganese, nickel, lanthanides such as, for example, samarium, europium, and terbium, or other metals having octahedral coordination geometry.
- Metal nitrates are convenient, although metal sulfates, metal carbonates, metal phosphates and other metal salts of oxyanions can be used.
- the solvent is generally selected so that both the organic reducing agent and the metal salt are soluble in the solvent. Methanol, ethanol, or other alcohols can be suitable depending on solubility of the organic reducing agent and the metal salt.
- solvent pH and temperature can be selected to enhance production of the metal cluster. Metal species associated with more acidic Lewis acids may react more favorably if the solvent pH is adjusted to become slightly basic, but a range of pH values from about 2 to about 13 may typically be used.
- the organic reducing agent (ORA) is typically selected to reduce the metal salt by, for example, reducing a constituent of the ligand to which a metallic species in the metal salt is bound.
- ORA organic reducing agent
- some suitable metal salts are metal nitrates, and the ORA is selected to reduce a nitrate group to a nitrite group.
- Representative ORAs include nitrosobenzene, nitroalkanes and bromonitoalkanes (from oximes), sulfoxides, and phosphines.
- ORAs include nitroso compounds that can be represented by the formula R—N ⁇ O, wherein R is an aliphatic or aromatic moiety. Nitrosamines having a chemical formula R 2 —N—N ⁇ O. In one embodiment, R includes at least one site of unsaturation, which may be conjugated to the nitrosamine moiety. For example, certain nitrosamines are directly attached to an alkenyl moiety. Other examples of conjugated nitrosamines include aryl nitrosamines, such as optionally substituted phenyl nitrosamines.
- aliphatic group includes alkyl, alkenyl, alkynyl, halogenated alkyl and cycloalkyl groups.
- a “lower aliphatic” group is a branched or unbranched aliphatic group having from 1 to 10 carbon atoms.
- aryl group refers to any carbon-based aromatic group including, but not limited to, benzene, naphthalene, etc.
- aromatic also includes “heteroaryl group,” which is defined as an aromatic group that has at least one heteroatom incorporated within the ring of the aromatic group. Examples of heteroatoms include, but are not limited to, nitrogen, oxygen, sulfur, and phosphorous.
- the aryl group can be substituted with one or more groups including, but not limited to, alkyl, alkynyl, alkenyl, aryl, halide, nitro, amino, ester, ketone, aldehyde, hydroxy, carboxylic acid, or alkoxy, or the aryl group can be unsubstituted.
- ORAs such as the oxidation of nitrosoaromatics to nitroaromatics
- Functional group tolerance can be evaluated and functional groups selected based on the scheme illustrated in Formula 2. As shown in Formula 2, diverse substrates including electron-withdrawing to electron-donating substituents can be evaluated and selected.
- oximes and nitrosoalkanes Synthesis based on oximes and nitrosoalkanes is illustrated in Formula 5. Since oximes and nitrosoalkanes are tautomers, and equilibrium lies far to the oxime, a mild oxidation of a nitrosoalkane to a nitroalkane can be accomplished using metal nitrates, provided sufficient nitrosoalkane is present in solution.
- a wide array of oximes is readily available and can be based on aliphatic or aromatic moieties such as those described with reference to nitrosamines.
- bromination of an oxime to a bromonitroso compound, followed by mild oxidation to a bromonitroalkane can be used to produce a nitroalkane upon reduction with sodium borohydride.
- This procedure is illustrated in Formula 6.
- NBS represents n-bromosuccinimide
- R represents any of the moieties described previously.
- Combinations of metal salts of metals M and N can be used to produce an N a M b cluster.
- N a M b cluster For example, while a cluster of 13 gallium atoms has been produced, in other syntheses, a cluster based on 7 gallium atoms and 6 indium atoms was produced.
- Other binary, tertiary, or higher order clusters can also be produced.
- Ga(NO 3 ) 3 .(H 2 O) is used as a reagent for the mild conversion of nitrosobenzene to nitrobenzene, forming crystals of a nitrate deficient gallium cluster.
- other inorganic clusters can be made, and functional groups other than the nitroso group can be used for the organic portion of the reaction.
- the symbols ⁇ and ⁇ 3 refer to the numbers of gallium atoms bridged by the OH groups, with ⁇ referring to the 18 OH groups that bridge two gallium atoms and ⁇ 3 referring to the six OH groups that bridge three gallium atoms.
- ⁇ 2 is used to denote groups bridging two gallium atoms instead of ⁇ . The same notation can be used in describing other cluster compounds as well.
- Ga 13 In the representative synthesis of a gallium cluster illustrated in Formula 7, robust crystals of [Ga 13 ( ⁇ 3 -OH) 6 ( ⁇ -OH) 18 (H 2 O) 24 ](NO 3 ) 15 .6H 2 O (referred to herein as Ga 13 ) were obtained in 65% yield from slow evaporation at room temperature of a methanolic solution of hydrated Ga(NO 3 ) 3 in the presence of stoichiometric amounts of nitrosobenzene.
- the nitrosobenzene acts as a scavenger of nitrate ions and facilitates the synthesis of Ga 13 via a redox reaction in which the nitrosobenzene is oxidized to nitrobenzene with concomitant reduction of some of the nitrate counterions LC-MS and 1 H NMR data verified that nitrobenzene was formed during the reaction. Furthermore, it is known that nitric acid can oxidize nitroso derivatives into the corresponding nitro compounds. This procedure represents a milder form of this reaction, in which a nitrate oxidizes nitrosobenzene at a slightly acidic pH.
- the remaining gallium-containing species form a higher nuclearity cluster where the ratio of nitrate to gallium(III) is less than 3:1—in this case, the stoichiometric ratio is 15:13.
- the solid state structure of Ga 13 is shown in FIGS. 1A-2B .
- the gallium cluster compound crystallizes as the Keggin-like cluster similar to other tridecameric gallium clusters stabilized by supporting ligands, wherein the central gallium is octahedral and surrounded by two concentric rings of six gallium ions each, with bridging hydroxo ligands between them.
- the cluster is capped on its periphery by 24 aquo ligands generating a nanoscale disk-like compound with a diameter of about 1.81 nm and a thickness of about 1.03 nm.
- Ga 13 is expected to persist in solution.
- Ga 13 is water-soluble, and upon recrystallization from aqueous solution, Ga 13 is regenerated, rather than decomposing to a mixture of Ga 2 O 3 , Ga(O)OH, Ga(OH) 3 and/or Ga(NO 3 ) 3 .
- the Keggin-like Al 13 cluster has been conventionally synthesized as both the Cl-salt and with supporting aminocarboxylate ligands.
- conventional synthesis methods are difficult and require months to complete.
- the procedure describe herein for the formation of Ga 13 clusters by the organic oxidation of nitrosobenzene and crystallization of the Ga 13 cluster can be viewed as a generic reaction applicable to the synthesis of isostructural analogous Al 13 clusters or other isotructural clusters.
- the Al 13 cluster can be isolated in less than 2 weeks.
- the general strategy for making a cluster is to dissolve both the metal salt (13 equivalents) and the nitrosobenzene (24 equivalents) in methanol, mix them together and, for aluminum clusters, add 0.1 equivalent of methanolic KOH to adjust pH. The mixture is allowed to slowly evaporate over 4-8 days, yielding large single crystals (about 65% yield) for single crystal X-ray diffraction and elemental analysis.
- Al 13 clusters are produced having a formula [Al 13 ( ⁇ 3 -OH) 6 ( ⁇ -OH) 18 (H 2 O) 24 ](NO 3 ) 15 , wherein ⁇ 3 and ⁇ refer to OH groups that bridge 3 or 2 aluminum ions, respectively.
- the aluminum cluster reaction proceeds with about a 65% yield with respect to metal salt. Selection of the numbers of equivalents of the reactants can be associated with reaction rate, but typically the same product is obtained with a range of equivalents of the reactants.
- This procedure can be applied to other metals and metal mixtures to synthesize clusters containing gallium and/or indium.
- Mixing thirteen equivalents of gallium nitrate with nitrosobenzene in methanol with no added base produced the Ga 13 cluster.
- a mixed metal cluster of gallium and indium was synthesized using 7 equivalents of gallium nitrate and 6 of indium nitrate to produce Ga 7 In 6 clusters with a chemical formula of [Ga 7 In 6 ( ⁇ 3 -OH) 6 ( ⁇ -OH) 18 (H 2 O) 24 ](NO 3 ) 15 .
- These clusters have both been produced and structurally characterized by single crystal X-ray diffraction.
- the presence of nitrobenzene as a product was verified by 1 H NMR spectroscopy and LC mass spectrometry. The production of these clusters is described with additional detail below, and the general procedure is outlined in Formula 8.
- Formula 9 illustrates a synthesis of Al 13 using a method similar to that described above for Ga 13 .
- the polymerization equilibria of aluminum species is dependent on pH, concentration of base and aluminum (they form readily with [Al 3+ ]>10 ⁇ 5 M), stirring rate, temperature, aging time and rate of base addition. Because aluminum is more acidic than gallium, the concentration of Al(NO 3 ) 3 and pH may be adjusted (from pH 2-13).
- M 13 nanoclusters can be formed by the treatment of a hydrated M(NO 3 ) 3 with nitrosobenzene.
- In 13 clusters and binary clusters such as Ga 7 In 6 can be produced as illustrated in Formula 10.
- Ga 7 In 6 has been produced such that the seven Ga ions are situated at the innermost sites in the cluster.
- Other clusters include GeAl 12 , Fe 13 , and Mn 13 clusters, and can be produced using, for example, either a hydrated metal nitrate or in the presence of water.
- higher nuclearity versions of these cluster types can be formed.
- these larger clusters are formed by stabilizing the core with peripheral ligands or by exposure of smaller nuclearity clusters to base over time.
- Stable M 13 or other clusters can be exposed to an ORA such as nitrosobenzene and base in a methanolic or aqueous solution.
- Slow evaporation and/or heating can yield higher nuclearity clusters devoid of stabilizing non-aquo ligands as illustrated in Formula 11.
- clusters based on 13 or 30 metal ions have been described, other cluster configurations can be selected. For example, clusters having 8, 13, 30, or 32 metal ions can be produced.
- compositions are prepared for administration to a subject and include a diagnostically effective amount of one or more of the currently disclosed compounds.
- the diagnostically effective amount of a disclosed compound will depend on the route of administration, the type of mammal that is the subject and the physical characteristics of the subject being investigated. Specific factors that can be taken into account include disease severity and stage, weight, diet and concurrent medications. The relationship of these factors to determining a diagnostically effective amount of the disclosed compounds is understood by those of ordinary skill in the art. Therapeutically effective amounts are subject to similar considerations.
- any of the nanocluster compositions described herein can be combined with a pharmaceutically acceptable carrier to form a pharmaceutical composition.
- Pharmaceutical carriers are known to those skilled in the art. These most typically would be standard carriers for administration of compositions to humans, including solutions such as sterile water, saline, and buffered solutions at physiological pH. The compositions could also be administered intramuscularly, subcutaneously, or in an aerosol form. Other compounds will be administered according to standard procedures used by those skilled in the art.
- Nanoclusters intended for pharmaceutical delivery can be formulated in a pharmaceutical composition.
- Pharmaceutical compositions can include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like in addition to the molecule of choice.
- Pharmaceutical compositions can also include one or more additional active ingredients such as antimicrobial agents, anti-inflammatory agents, anesthetics, and the like.
- Pharmaceutical formulations can include additional components, such as carriers.
- the pharmaceutically acceptable carriers useful for these formulations are conventional. Remington's Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, Pa., 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of the compounds herein disclosed.
- parenteral formulations usually contain injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
- injectable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
- physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like
- solid compositions for example, powder, pill, tablet, or capsule forms
- conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate.
- compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
- non-toxic auxiliary substances such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
- Diagnostic tests based on gallium nanoclusters permit investigation of how a subject's body processes the composition containing the nanoclusters, and typically include images based on radioactivity associated with the nanoclusters.
- the nanoclusters can be chemically bound to a substance that has a particular processing characteristic within the body (i.e., the substance acts as a tracer). Presence of disease or abnormality is then associated with abnormal or unusual processing of the substance by the body. In some examples, accumulation of a substance is enhanced due to disease while in other examples, the substance is excluded from a region in which it would normally accumulate. Accumulation of a substance is associated with a “hot spot” in an image while exclusion of a substance is associated with a “cold spot.”
- nanoclusters can be attached to a substance that is preferentially accumulated in a particular body region or tissue (such as for example, bone, kidneys, lungs, etc.).
- the accumulation (or lack thereof) can be used in imaging.
- Increased physiological function such as associated with, for example, bone fracture, can result in abnormally high accumulation of the substance and produces a hot spot in an image.
- the substance is excluded due to disease or injury.
- Nanoclusters and nanocluster compositions can be used in in-vivo and in-vitro analysis.
- In-vivo analysis is based on subject evaluations using, for example, gamma camera imaging or non-imaging measurement of radioactivity in the subject.
- In-vitro analysis is typically based on samples extracted from a subject such as, for examples, blood or urine samples.
- Radioisotopes can be produced using, for example, a nuclear reactor or a cyclotron.
- Gallium 67 can be produced by bombardment of zinc with energetic protons using a cyclotron.
- a zinc target is exposed so as to be substantially free of stable gallium isotopes.
- Other isotopes of gallium or radioactive indium can also be used in imaging applications.
- compositions can be applied for patient imaging in various ways.
- a liquid containing a nanocluster composition can be injected intravenously.
- Subcutaneous injection can also be used, wherein the composition is injected under the skin.
- intrasynovial injection is used, wherein the composition is injected into a joint space.
- a composition is inhaled for use in lung investigations or ingested for evaluation and study of digestive tract function.
- a composition can be applied topically.
- a composition can be configured as, for example, an aerosol dispersion, an ingestible substance (included with a food), or in a sterile, injectable carrier.
- the gallium compounds described herein may be formed using one or more gallium isotopes such as the radioactive isotopes gallium 66, gallium 67, and/or gallium 68.
- Such radioactive gallium compounds may be used in imaging applications in, for example, nuclear medicine.
- Gallium 67 emits gamma radiation, and the gamma emission from such compounds may be applied to gamma scintigraphy in which a gamma camera or a SPECT (single photon emission computed tomography) camera is used for imaging.
- SPECT single photon emission computed tomography
- such compounds may be used in positron emission tomography (PET) in which photons produced in positron decay are detected.
- PET positron emission tomography
- Such compounds may be injected into patients, and a distribution of compound in the patient detected.
- Such compounds can be referred to as contrast agents in these and other imaging techniques. Similar methods may be used to form radioactive indium compounds.
- gamma-cameras have consisted of a gamma-ray detector, such as a single large sodium iodide NaI(Tl) scintillation crystal, coupled with an imaging sub-system such as an array of photomultiplier tubes and associated electronics.
- a gamma-ray detector such as a single large sodium iodide NaI(Tl) scintillation crystal
- an imaging sub-system such as an array of photomultiplier tubes and associated electronics.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Geology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
- This application claims the benefit of U.S. Provisional Patent Application Ser. No. 60/651,582, filed Feb. 9, 2005, which is incorporated herein by reference.
- The disclosure pertains to methods of producing oxo/hydroxo-bridged metal aquo nanoclusters.
- Several types of Keggin structures are known. Representative Keggin structures having a central tetrahedral Al(O)4 core are illustrated in
FIGS. 6A-6C . These structures correspond to so-called ε-Keggin (Al13), δ-Keggin (Al13), and an Al30 cluster. These and other Keggin structures are described in Casey et al., Reviews in Mineralogy & Geochemistry 44:167-190 (2001). - While these Keggin structures have potential practical applications, the synthesis of these structures limits their use. Synthesis of Keggin-like clusters typically involves lengthy reaction times and harsh reaction conditions. For example, synthesis of the Keggin-like Al cluster [Al13(μ3-OH)6(μ2-OH)18(H2O)24]Cl15 requires a 4-5 month synthesis/crystallization procedure as reported by Seichter et al., Eur. J. Inorg. Chem. (1998). Synthesis of the Keggin-like Al cluster [Al8(μ3-OH)2(μ2-OH)12(H2O)18](SO4)5 requires a 7 year synthesis/crystallization procedure as reported by Casey et al., Inorg. Chem. (2005). Synthesis of the Keggin-like Al cluster [Al15(μ3-O)4(μ3-OH)6(μ2-OH)14(hpdta)]3 requires an 8 day ligand-shell stabilized synthesis as reported in Schmitt et al., Angew. Chem. (2001). For convenience, diagrams of these Al(O)6 core materials are shown in
FIGS. 7A-7C . - Because of the limitations of conventional synthesis, improved synthesis methods are needed, and new synthetic products made available by such improved synthesis methods.
- Nanoscale inorganic clusters can be formed synergistically with a mild organic oxidation reaction. A tridecameric cluster [Ga13(μ3-OH)6(μ-OH)18(H2O)24](NO3)15 (referred to herein as Ga13) forms when a mild organic reducing agent (such as nitrosobenzene) facilitates the conversion. This is an example of an organic reaction mediating an inorganic transformation, and provides a link between organic and inorganic synthesis that allows both processes to occur under aerobic, ambient conditions with good yields. Previous syntheses of inorganic clusters suffer from extremely long reaction times (months to years), harsh conditions, and/or poor yields. The mild organic oxidation reaction can be tolerant to many functional groups, and other mild organic oxidation reactions can be similarly implemented.
- The representative clusters described herein have applications in areas ranging from environmental chemistry (mimics for mineral surfaces) to the cracking of gas oil (pillaring agents for montmorillonite clay catalysts). Other nanocluster applications include: models for the active sites of minerals for catalysis, single molecule magnets (with magnetic or paramagnetic metal ions), magnetic memory devices, conductive/semiconductive metal oxide layers for circuits and integrated circuits, high-density metal-based contrast agents (e.g., 67Ga positron emission tomography (PET) contrast agents), osmotic-type molecular transport phenomena using the high charge of the clusters, environmental remediation of toxic metal ions, and the use of the clusters as synthons for materials via aquo ligand exchange reactions.
- Conventional syntheses of these clusters typically involve traditional inorganic methods: ligand exchange, oxidation of metal(0) starting materials, salt metathesis, acid/base hydrolysis, etc. Disclosed herein are novel synthetic strategies in which a simple organic reaction is used to facilitate the formation of tridecameric clusters such as gallium clusters. For example, by using Ga(NO3)3.(H2O)6 as a reagent for the extremely mild conversion of nitrosobenzene to nitrobenzene, robust crystals of the nitrate-deficient gallium cluster [Ga13(μ3-OH)6(μ-OH)18(H2O)24](NO3)15 have been formed as described in detail below. The novel synthesis described herein can generate, for example, gallium, aluminum, or other clusters with high yields in times ranging from about a few hours, a few days, or a few weeks under ambient, aerobic conditions.
- Solid state and solution investigations of group 13 clusters reveal that the majority of the compounds are polyoxocations based upon the modified-Keggin structure, which possesses octahedral peripheral metal cations bridged to a central tetrahedral M(III) ion. While the presence of chelating organic ligands stabilizes a range of “Keggin-like” polynuclear clusters (where the central metal ion is octahedral rather than tetrahedral) and allows for their crystallization, isolation of the purely inorganic Ga(III) clusters analogous to the Keggin-like Al13 clusters has not been previously accomplished. As described herein, a straightforward method has been developed to prepare clusters such as Ga13 using a simple organic reaction to drive the formation of the crystalline inorganic cluster.
- The present disclosure is directed to synthesis methods that can form previously synthesized inorganic clusters or previously unavailable inorganic clusters. The synthesis methods are typically based on functional group tolerant organic oxidations that occur under “mild” conditions, i.e., typically do not require temperature, pressure, or pH extremes, or lengthy reaction times. Inorganic clusters based on gallium, aluminum, and combinations of indium and gallium are described in detail. For convenience, these clusters are referred to as M13 or NAMB, wherein M, N refer to metallic species, and for the binary cluster NAMB, A+B=13. Representative clusters include Ga13, A13, Ga7In6, and GaAl12.
- One aspect of the present disclosure includes novel compounds, compositions and methods for using such compounds and compositions for use in scintigraphy or PET or other diagnostic imaging applications.
- The foregoing and other features and advantages of the disclosed technology will become more apparent from the following detailed description, which proceeds with reference to the accompanying drawings.
-
FIGS. 1A-1B are space-filling representations of a single crystal X-ray structure of a Ga13 nanocluster. -
FIGS. 2A-2B are wireframe representations of a single crystal X-ray structure of a Ga13 nanocluster. -
FIG. 3A is an X-ray powder diffraction pattern obtained from Ga13 produced as described herein. -
FIG. 3B is an X-ray power diffraction pattern obtained by calculation. -
FIGS. 4A-4B are space-filling representations of Al13 derived from the measured single crystal X-ray structure of Al13. -
FIGS. 5A-5B are space-filling representations of In6Ga7 derived from the measured single crystal X-ray structure of In6Ga7. -
FIGS. 6A-6C are space-filling representations of ε-Keggin, Al13, δ-Keggin (Al13), and an Al30 cluster, respectively. -
FIGS. 7A-7C illustrate [Al13(μ3-OH)6(μ2-OH)18(H2O)24]Cl15, [Al8(μ3-OH)2(μ2-OH)12(H2O)18](SO4)5, and [Al15(μ3-O)4(μ3-OH)6(μ2-OH)14(hpdta)]3, respectively. - The following explanations of terms and methods are provided to better describe the present compounds, compositions, and methods, and to guide those of ordinary skill in the art in the practice of the present disclosure. It is also to be understood that the terminology used in the disclosure is for the purpose of describing particular embodiments and examples only and is not intended to be limiting.
- Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.
- In this specification and in the claims which follow, reference will be made to a number of terms which shall be understood to have the following meanings. “Optional” or “optionally” means that the subsequently described event or circumstance can but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. “Nanoscale” cluster compounds or “nanocluster” generally refers to clusters having dimensions of from about 0.1 nm to 200 nm, preferably between about 0.2 nm and 100 nm, more preferably between about 0.5 nm and 50 nm, and still more preferably between about 1 nm and 5 nm. In one representative example, a gallium nanocluster is disk shaped and has a diameter of about 2 nm and a thickness of about 1 nm. Materials are referred to as soluble or appreciably soluble if millimolar concentrations can be achieved under typical reaction conditions such as ambient temperatures.
-
- Metal salts generally are selected from a group consisting of salts of aluminum, germanium, indium, gallium, iron, manganese, nickel, lanthanides such as, for example, samarium, europium, and terbium, or other metals having octahedral coordination geometry. Metal nitrates are convenient, although metal sulfates, metal carbonates, metal phosphates and other metal salts of oxyanions can be used. The solvent is generally selected so that both the organic reducing agent and the metal salt are soluble in the solvent. Methanol, ethanol, or other alcohols can be suitable depending on solubility of the organic reducing agent and the metal salt. Although not shown in Formula 1, solvent pH and temperature can be selected to enhance production of the metal cluster. Metal species associated with more acidic Lewis acids may react more favorably if the solvent pH is adjusted to become slightly basic, but a range of pH values from about 2 to about 13 may typically be used.
- The organic reducing agent (ORA) is typically selected to reduce the metal salt by, for example, reducing a constituent of the ligand to which a metallic species in the metal salt is bound. For example, some suitable metal salts are metal nitrates, and the ORA is selected to reduce a nitrate group to a nitrite group. Representative ORAs include nitrosobenzene, nitroalkanes and bromonitoalkanes (from oximes), sulfoxides, and phosphines.
- Some suitable ORAs include nitroso compounds that can be represented by the formula R—N═O, wherein R is an aliphatic or aromatic moiety. Nitrosamines having a chemical formula R2—N—N═O. In one embodiment, R includes at least one site of unsaturation, which may be conjugated to the nitrosamine moiety. For example, certain nitrosamines are directly attached to an alkenyl moiety. Other examples of conjugated nitrosamines include aryl nitrosamines, such as optionally substituted phenyl nitrosamines.
- The term “aliphatic group” includes alkyl, alkenyl, alkynyl, halogenated alkyl and cycloalkyl groups. A “lower aliphatic” group is a branched or unbranched aliphatic group having from 1 to 10 carbon atoms.
- The term “aryl group” refers to any carbon-based aromatic group including, but not limited to, benzene, naphthalene, etc. The term “aromatic” also includes “heteroaryl group,” which is defined as an aromatic group that has at least one heteroatom incorporated within the ring of the aromatic group. Examples of heteroatoms include, but are not limited to, nitrogen, oxygen, sulfur, and phosphorous. The aryl group can be substituted with one or more groups including, but not limited to, alkyl, alkynyl, alkenyl, aryl, halide, nitro, amino, ester, ketone, aldehyde, hydroxy, carboxylic acid, or alkoxy, or the aryl group can be unsubstituted.
- The oxidation associated with such ORAs, such as the oxidation of nitrosoaromatics to nitroaromatics, are generally a mild oxidations that exhibit wide functional group tolerance. Functional group tolerance can be evaluated and functional groups selected based on the scheme illustrated in
Formula 2. As shown inFormula 2, diverse substrates including electron-withdrawing to electron-donating substituents can be evaluated and selected. - There are numerous mild organic oxidation reactions that can be used to drive cluster synthesis such as, for example, the oxidation of phosphines to phosphine oxides and sulfoxides to sulfones. Examples are illustrated in Formula 3 and Formula 4 below. With such reactions, synthesis of an inorganic nanocluster drives the organic reaction.
- Synthesis based on oximes and nitrosoalkanes is illustrated in
Formula 5. Since oximes and nitrosoalkanes are tautomers, and equilibrium lies far to the oxime, a mild oxidation of a nitrosoalkane to a nitroalkane can be accomplished using metal nitrates, provided sufficient nitrosoalkane is present in solution. A wide array of oximes is readily available and can be based on aliphatic or aromatic moieties such as those described with reference to nitrosamines. - In another example, bromination of an oxime to a bromonitroso compound, followed by mild oxidation to a bromonitroalkane can be used to produce a nitroalkane upon reduction with sodium borohydride. This procedure is illustrated in Formula 6. In Formula 6, NBS represents n-bromosuccinimide, and R represents any of the moieties described previously.
- Combinations of metal salts of metals M and N can be used to produce an NaMb cluster. For example, while a cluster of 13 gallium atoms has been produced, in other syntheses, a cluster based on 7 gallium atoms and 6 indium atoms was produced. Other binary, tertiary, or higher order clusters can also be produced. For binary tridecameric clusters, a sum of numbers of M-type ions and N-type ions (Na and Nb, respectively) is thirteen, so that various numbers of atoms of each of the binary constituent can be used, subject to the constraint Na+Nb=13. Similar considerations apply to tertiary clusters, wherein a sum Na+Nb+Nc=13, wherein Nc refers to a number of ions of a third metallic constituent.
- In an example shown in Formula 7, Ga(NO3)3.(H2O) is used as a reagent for the mild conversion of nitrosobenzene to nitrobenzene, forming crystals of a nitrate deficient gallium cluster. In additional examples, other inorganic clusters can be made, and functional groups other than the nitroso group can be used for the organic portion of the reaction.
In Formula 7, the symbols μ and μ3 refer to the numbers of gallium atoms bridged by the OH groups, with μ referring to the 18 OH groups that bridge two gallium atoms and μ3 referring to the six OH groups that bridge three gallium atoms. In some examples, μ2 is used to denote groups bridging two gallium atoms instead of μ. The same notation can be used in describing other cluster compounds as well. - In the representative synthesis of a gallium cluster illustrated in Formula 7, robust crystals of [Ga13(μ3-OH)6(μ-OH)18(H2O)24](NO3)15.6H2O (referred to herein as Ga13) were obtained in 65% yield from slow evaporation at room temperature of a methanolic solution of hydrated Ga(NO3)3 in the presence of stoichiometric amounts of nitrosobenzene. In this process the nitrosobenzene acts as a scavenger of nitrate ions and facilitates the synthesis of Ga13 via a redox reaction in which the nitrosobenzene is oxidized to nitrobenzene with concomitant reduction of some of the nitrate counterions LC-MS and 1H NMR data verified that nitrobenzene was formed during the reaction. Furthermore, it is known that nitric acid can oxidize nitroso derivatives into the corresponding nitro compounds. This procedure represents a milder form of this reaction, in which a nitrate oxidizes nitrosobenzene at a slightly acidic pH. As a result of consumption of some of the nitrate counterions of Ga(NO3)3, the remaining gallium-containing species form a higher nuclearity cluster where the ratio of nitrate to gallium(III) is less than 3:1—in this case, the stoichiometric ratio is 15:13.
- The solid state structure of Ga13 is shown in
FIGS. 1A-2B . The gallium cluster compound crystallizes as the Keggin-like cluster similar to other tridecameric gallium clusters stabilized by supporting ligands, wherein the central gallium is octahedral and surrounded by two concentric rings of six gallium ions each, with bridging hydroxo ligands between them. The cluster is capped on its periphery by 24 aquo ligands generating a nanoscale disk-like compound with a diameter of about 1.81 nm and a thickness of about 1.03 nm. Ga13 is expected to persist in solution. Ga13 is water-soluble, and upon recrystallization from aqueous solution, Ga13 is regenerated, rather than decomposing to a mixture of Ga2O3, Ga(O)OH, Ga(OH)3 and/or Ga(NO3)3. - Slow evaporation of a 5 mL methanolic solution of Ga(NO3)3.6H2O (0.47 g, 0.13 mmol) in the presence of nitrosobenzene (0.025 g, 0.24 mmol) yielded 0.018 g (0.0065 mmol, 65%) of Ga13. Crystals of the product were shown to be representative of the bulk by comparison of the X-ray powder pattern collected on a fresh sample with the corresponding pattern calculated from the crystal structure. X-ray powder spectra based on the reaction product and calculated based on the crystal structure are shown in
FIGS. 3-4 , respectively. Various Ga13 cluster parameters based on single crystal X-ray diffraction measurements are listed in the table below. -
- Ga13 Summary
- Avg. Ga—O: 1.97 Å
- Trigonal, R-3
- α=20.214(3) Å, c=18.353(4) Å
- α=β=90.00°, γ=120°
- V=6494(2) Å 3, Z=3
- R1=0.0349
- wR2(all)=0.0988
- GOF=1.035
- In the synthesis, the original light blue solution of nitrosobenzene and Ga(NO3)3.6H2O turns pale green after one day indicating oxidation of nitrosobenzene to nitrobenzene. The pH of a solution of Ga13 dissolved in water (1.6 nM) was measured as 2.28. Dissolution of Ga13 in water followed by recrystallization via evaporation resulted in the sole formation of Ga13 as determined by single crystal unit cell determination and X-ray powder diffraction. The entire synthesis can be completed in less than a week. Attempts to produce Ga13 in the presence of water alone, pyridine, 2,6-lutidine, and nitrobenzene were unsuccessful and resulted in the formation of Ga(NO3)3 or GaL2(NO3)3, wherein L is 2,6-lutidine.
- The Keggin-like Al13 cluster has been conventionally synthesized as both the Cl-salt and with supporting aminocarboxylate ligands. However, conventional synthesis methods are difficult and require months to complete. The procedure describe herein for the formation of Ga13 clusters by the organic oxidation of nitrosobenzene and crystallization of the Ga13 cluster can be viewed as a generic reaction applicable to the synthesis of isostructural analogous Al13 clusters or other isotructural clusters. Using the disclosed organic mediated reaction, the Al13 cluster can be isolated in less than 2 weeks.
- The general strategy for making a cluster is to dissolve both the metal salt (13 equivalents) and the nitrosobenzene (24 equivalents) in methanol, mix them together and, for aluminum clusters, add 0.1 equivalent of methanolic KOH to adjust pH. The mixture is allowed to slowly evaporate over 4-8 days, yielding large single crystals (about 65% yield) for single crystal X-ray diffraction and elemental analysis. For aluminum nitrate, Al13 clusters are produced having a formula [Al13(μ3-OH)6(μ-OH)18(H2O)24](NO3)15, wherein μ3 and μ refer to OH groups that
bridge 3 or 2 aluminum ions, respectively. The aluminum cluster reaction proceeds with about a 65% yield with respect to metal salt. Selection of the numbers of equivalents of the reactants can be associated with reaction rate, but typically the same product is obtained with a range of equivalents of the reactants. - This procedure can be applied to other metals and metal mixtures to synthesize clusters containing gallium and/or indium. Mixing thirteen equivalents of gallium nitrate with nitrosobenzene in methanol with no added base produced the Ga13 cluster. A mixed metal cluster of gallium and indium was synthesized using 7 equivalents of gallium nitrate and 6 of indium nitrate to produce Ga7In6 clusters with a chemical formula of [Ga7In6(μ3-OH)6(μ-OH)18(H2O)24](NO3)15. These clusters have both been produced and structurally characterized by single crystal X-ray diffraction. The presence of nitrobenzene as a product was verified by 1H NMR spectroscopy and LC mass spectrometry. The production of these clusters is described with additional detail below, and the general procedure is outlined in Formula 8.
- Formula 9 illustrates a synthesis of Al13 using a method similar to that described above for Ga13. The polymerization equilibria of aluminum species is dependent on pH, concentration of base and aluminum (they form readily with [Al3+]>10−5 M), stirring rate, temperature, aging time and rate of base addition. Because aluminum is more acidic than gallium, the concentration of Al(NO3)3 and pH may be adjusted (from pH 2-13).
Some of the measured single crystal x-ray structural properties of these aluminum clusters are listed in the table below. -
- Al13 Summary
- Triclinic, P-1
- α=12.86 Å, b=13.17 Å, c=13.43 Å
- α=78.27°, β=74.15°, γ=87.96°
- V=2143 Å 3, Z=1
- Other M13 nanoclusters can be formed by the treatment of a hydrated M(NO3)3 with nitrosobenzene. For example, In13 clusters and binary clusters such as Ga7In6 can be produced as illustrated in
Formula 10. Ga7In6 has been produced such that the seven Ga ions are situated at the innermost sites in the cluster. A summary of Ga7In6 properties based on single crystal X-ray diffraction measurements is included in the table below. Other clusters include GeAl12, Fe13, and Mn13 clusters, and can be produced using, for example, either a hydrated metal nitrate or in the presence of water. -
- Ga7In6 Summary
- Trigonal, R-3
- α=20.41 Å, b=20.41 Å, c=18.36 Å
- α=β=90°, γ=120°
- V=6621 Å 3,Z=3
- In addition to the clusters described above, higher nuclearity versions of these cluster types can be formed. Typically these larger clusters are formed by stabilizing the core with peripheral ligands or by exposure of smaller nuclearity clusters to base over time. Stable M13 or other clusters can be exposed to an ORA such as nitrosobenzene and base in a methanolic or aqueous solution. Slow evaporation and/or heating can yield higher nuclearity clusters devoid of stabilizing non-aquo ligands as illustrated in Formula 11.
While clusters based on 13 or 30 metal ions have been described, other cluster configurations can be selected. For example, clusters having 8, 13, 30, or 32 metal ions can be produced. - While there are numerous applications of the disclosed compounds, one of particular significance is use in pharmaceutical compositions. Such compositions are prepared for administration to a subject and include a diagnostically effective amount of one or more of the currently disclosed compounds. The diagnostically effective amount of a disclosed compound will depend on the route of administration, the type of mammal that is the subject and the physical characteristics of the subject being investigated. Specific factors that can be taken into account include disease severity and stage, weight, diet and concurrent medications. The relationship of these factors to determining a diagnostically effective amount of the disclosed compounds is understood by those of ordinary skill in the art. Therapeutically effective amounts are subject to similar considerations.
- Any of the nanocluster compositions described herein can be combined with a pharmaceutically acceptable carrier to form a pharmaceutical composition. Pharmaceutical carriers are known to those skilled in the art. These most typically would be standard carriers for administration of compositions to humans, including solutions such as sterile water, saline, and buffered solutions at physiological pH. The compositions could also be administered intramuscularly, subcutaneously, or in an aerosol form. Other compounds will be administered according to standard procedures used by those skilled in the art.
- Nanoclusters intended for pharmaceutical delivery can be formulated in a pharmaceutical composition. Pharmaceutical compositions can include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like in addition to the molecule of choice. Pharmaceutical compositions can also include one or more additional active ingredients such as antimicrobial agents, anti-inflammatory agents, anesthetics, and the like. Pharmaceutical formulations can include additional components, such as carriers. The pharmaceutically acceptable carriers useful for these formulations are conventional. Remington's Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, Pa., 15th Edition (1975), describes compositions and formulations suitable for pharmaceutical delivery of the compounds herein disclosed.
- In general, the nature of the carrier will depend on the particular mode of administration being employed. For instance, parenteral formulations usually contain injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. For solid compositions (for example, powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically-neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
- Diagnostic tests based on gallium nanoclusters permit investigation of how a subject's body processes the composition containing the nanoclusters, and typically include images based on radioactivity associated with the nanoclusters. For example, the nanoclusters can be chemically bound to a substance that has a particular processing characteristic within the body (i.e., the substance acts as a tracer). Presence of disease or abnormality is then associated with abnormal or unusual processing of the substance by the body. In some examples, accumulation of a substance is enhanced due to disease while in other examples, the substance is excluded from a region in which it would normally accumulate. Accumulation of a substance is associated with a “hot spot” in an image while exclusion of a substance is associated with a “cold spot.”
- For example, nanoclusters can be attached to a substance that is preferentially accumulated in a particular body region or tissue (such as for example, bone, kidneys, lungs, etc.). The accumulation (or lack thereof) can be used in imaging. Increased physiological function such as associated with, for example, bone fracture, can result in abnormally high accumulation of the substance and produces a hot spot in an image. In other examples, the substance is excluded due to disease or injury.
- Nanoclusters and nanocluster compositions can be used in in-vivo and in-vitro analysis. In-vivo analysis is based on subject evaluations using, for example, gamma camera imaging or non-imaging measurement of radioactivity in the subject. In-vitro analysis is typically based on samples extracted from a subject such as, for examples, blood or urine samples.
- Radioisotopes can be produced using, for example, a nuclear reactor or a cyclotron. Gallium 67 can be produced by bombardment of zinc with energetic protons using a cyclotron. In some cases, a zinc target is exposed so as to be substantially free of stable gallium isotopes. Other isotopes of gallium or radioactive indium can also be used in imaging applications.
- Compositions can be applied for patient imaging in various ways. For example, a liquid containing a nanocluster composition can be injected intravenously. Subcutaneous injection can also be used, wherein the composition is injected under the skin. In other examples, intrasynovial injection is used, wherein the composition is injected into a joint space. In other examples, a composition is inhaled for use in lung investigations or ingested for evaluation and study of digestive tract function. In further examples, a composition can be applied topically. For a particular application, a composition can be configured as, for example, an aerosol dispersion, an ingestible substance (included with a food), or in a sterile, injectable carrier.
- The gallium compounds described herein may be formed using one or more gallium isotopes such as the radioactive isotopes gallium 66, gallium 67, and/or gallium 68. Such radioactive gallium compounds may be used in imaging applications in, for example, nuclear medicine. Gallium 67 emits gamma radiation, and the gamma emission from such compounds may be applied to gamma scintigraphy in which a gamma camera or a SPECT (single photon emission computed tomography) camera is used for imaging. Alternatively, such compounds may be used in positron emission tomography (PET) in which photons produced in positron decay are detected. In medical applications, such compounds may be injected into patients, and a distribution of compound in the patient detected. Such compounds can be referred to as contrast agents in these and other imaging techniques. Similar methods may be used to form radioactive indium compounds.
- Radiation emitted from the radionuclide inside the body is usually detected using a gamma camera. Traditionally, gamma-cameras have consisted of a gamma-ray detector, such as a single large sodium iodide NaI(Tl) scintillation crystal, coupled with an imaging sub-system such as an array of photomultiplier tubes and associated electronics.
- The technology has been described with reference to example embodiments. It will be apparent to those of ordinary skill in the art that changes and modifications may be made without departing from the teachings of this disclosure, and we claim all that is encompassed by the appended claims.
Claims (25)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/352,445 US20060199972A1 (en) | 2005-02-09 | 2006-02-09 | Methods for producing gallium and other oxo/hydroxo-bridged metal aquo clusters |
US12/541,889 US7927569B2 (en) | 2005-02-09 | 2009-08-14 | Methods for producing gallium and other oxo/hydroxo-bridged metal aquo clusters |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65158205P | 2005-02-09 | 2005-02-09 | |
US11/352,445 US20060199972A1 (en) | 2005-02-09 | 2006-02-09 | Methods for producing gallium and other oxo/hydroxo-bridged metal aquo clusters |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/541,889 Division US7927569B2 (en) | 2005-02-09 | 2009-08-14 | Methods for producing gallium and other oxo/hydroxo-bridged metal aquo clusters |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060199972A1 true US20060199972A1 (en) | 2006-09-07 |
Family
ID=36793807
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/352,445 Abandoned US20060199972A1 (en) | 2005-02-09 | 2006-02-09 | Methods for producing gallium and other oxo/hydroxo-bridged metal aquo clusters |
US12/541,889 Active US7927569B2 (en) | 2005-02-09 | 2009-08-14 | Methods for producing gallium and other oxo/hydroxo-bridged metal aquo clusters |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/541,889 Active US7927569B2 (en) | 2005-02-09 | 2009-08-14 | Methods for producing gallium and other oxo/hydroxo-bridged metal aquo clusters |
Country Status (2)
Country | Link |
---|---|
US (2) | US20060199972A1 (en) |
WO (1) | WO2006086747A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012054376A3 (en) * | 2010-10-19 | 2012-06-21 | LG Bionano, LLC | Metal ion nanoclusters |
US9370202B2 (en) | 2013-03-15 | 2016-06-21 | LG Bionano, LLC | Encapsulated metal ion nanoclusters |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5602268A (en) * | 1995-07-20 | 1997-02-11 | Mallinckrodt Medical, Inc. | Process for producing tungsten clusters |
US5641472A (en) * | 1995-07-20 | 1997-06-24 | Fung; Ella Y. | Tungsten clusters |
-
2006
- 2006-02-09 US US11/352,445 patent/US20060199972A1/en not_active Abandoned
- 2006-02-09 WO PCT/US2006/004958 patent/WO2006086747A2/en active Application Filing
-
2009
- 2009-08-14 US US12/541,889 patent/US7927569B2/en active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012054376A3 (en) * | 2010-10-19 | 2012-06-21 | LG Bionano, LLC | Metal ion nanoclusters |
US9375449B2 (en) | 2010-10-19 | 2016-06-28 | LG Bionano, LLC | Metal ion nanoclusters |
US9370202B2 (en) | 2013-03-15 | 2016-06-21 | LG Bionano, LLC | Encapsulated metal ion nanoclusters |
Also Published As
Publication number | Publication date |
---|---|
US7927569B2 (en) | 2011-04-19 |
WO2006086747A3 (en) | 2007-03-22 |
WO2006086747A2 (en) | 2006-08-17 |
US20100068117A1 (en) | 2010-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4954417B2 (en) | Synthesis and use of radioplatinum-labeled chemotherapeutic drugs | |
Craft et al. | Depleted and natural uranium: chemistry and toxicological effects | |
Kelsen et al. | Pharmacokinetics of gallium nitrate in man | |
EP0652885B1 (en) | Tetraazamacrocyclic metal complexes | |
Ong et al. | Stability and toxicity of tris-tolyl bismuth (v) dicarboxylates and their biological activity towards Leishmania major | |
US7927569B2 (en) | Methods for producing gallium and other oxo/hydroxo-bridged metal aquo clusters | |
EP4424793A1 (en) | Radioactive medical isotope labeled rare-earth doped nanomaterial, pet imaging diagnosis and treatment agent, preparation method therefor and application thereof | |
US20100056826A1 (en) | Radioactive diagnostic imaging agent | |
TW202120483A (en) | Method for producing radioactive metal complex | |
PT96336A (en) | 10- (2'-HYDROXY-3'-POLYOXYALQUIL) -1,4,7-TRISCARBOXYMETHYL-1,4,7,10-TETRAAZACYCODLODES, USED AS SWITCH-LIQUID LIGANTS TO FORM CHELATES WITH METALS, AND COMPLEXES METALLICS THAT CONTAIN THEM | |
RU2663286C1 (en) | Preparation for magnetic-resonance diagnostics of f cancerous diseases comprising deuterated 2-amino-2-methylpropionic acid and/or 2-(n-methylamino)-2-methylpropionic acid and a diagnostic method using the preparation | |
DE3724188C2 (en) | Metal-containing oligosaccharide polysulfates, process for their preparation and pharmaceutical compositions containing them | |
EP3714783B1 (en) | Preparation for magnetic resonance diagnostics for oncological diseases, comprising deuterated 2-amino-2-methylpropionic acid and/or 2-(n-methylamino)-2-methylpropionic acid, and diagnostic method using said preparation | |
EP0831934B1 (en) | Preparation and use of contrast agents | |
Einkauf et al. | Ion-Exchange Kinetics of Alpha-Zirconium Phosphate Nanoplatelets for Application in Targeted Alpha Therapy | |
Zakharanka | Physico-chemical properties of oxamic and glyoxylic acids and their affinity to lanthanides | |
EP3747874B1 (en) | Sodium saccharin having conjugated ligand, derivatives thereof and process for the preparation thereof | |
JP2851356B2 (en) | Porphyrin metal composite and its use | |
JPH0233018B2 (en) | ||
US20200376147A1 (en) | Sodium saccharin having conjugated ligand, derivatives thereof and process for the preparation thereof | |
EP0504339A1 (en) | USE OF RADIOACTIVE METAL ION COMPLEXES WITH all-cis-1,3,5-TRIAMINO-2,4,6-CYCLOHEXANTRIOL AND THEIR DERIVATES FOR X-RAY DIAGNOSIS AND IN TUMOR THERAPY AS WELL AS FOR PRODUCING X-RAY DIAGNOSTIC AND TUMOR THERAPY AGENTS | |
Myers et al. | 11C distribution in dogs visualized in situ after intravenous 11C-cyanide in high specific activity | |
JPS63239286A (en) | Novel pheophorbide derivative and tumor diagnostic agent | |
AU2001239024B2 (en) | Methods of synthesis and use of radiolabelled platinum chemotherapeutic agents | |
Hirsch et al. | A Review of Its Properties and Current Status in Nuclear Medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: STATE OF OREGON ACTING BY AND THROUGH THE STATE BO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JOHNSON, DARREN W.;HEALEY, ELISABETH RATHER;GATLIN, JASON T.;REEL/FRAME:017620/0881;SIGNING DATES FROM 20060412 TO 20060424 |
|
AS | Assignment |
Owner name: STATE OF OREGON ACTING BY AND THROUGH THE STATE BO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JOHNSON, DARREN W.;RATHER HEALEY, ELISABETH;GATLIN, JASON T.;REEL/FRAME:017935/0396;SIGNING DATES FROM 20060412 TO 20060424 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |